

# CITATION REPORT

List of articles citing

Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature

DOI: 10.1038/eye.2013.107

Eye, 2013, 27, 787-94.

**Source:** <https://exaly.com/paper-pdf/55922004/citation-report.pdf>

**Version:** 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
542	YouTube as a source of information about retinitis pigmentosa. <i>Eye</i> , <b>2014</b> , 28, 499-500	4.4	16
541	Reply to Dr Grzybowski. <i>Eye</i> , <b>2014</b> , 28, 501	4.4	1
540	Bevacizumab for choroidal neovascularization secondary to age-related macular degeneration and pathological myopia. <b>2014</b> , 14, 1837-48		10
539	The role of antibiotics in the prevention of post-intravitreal anti-VEGF endophthalmitis: primum non nocere!. <i>Eye</i> , <b>2014</b> , 28, 500	4.4	5
538	Retinal function and morphology in the rabbit eye after intravitreal injection of the TNF alpha inhibitor adalimumab. <b>2014</b> , 39, 1106-16		6
537	Anti-Angiogenic Drugs: Involvement in Cutaneous Side Effects and Wound-Healing Complication. <b>2014</b> , 3, 635-646		16
536	Retinopathy of prematurity. <b>2014</b> , 61, 567-77		4
535	Natural product inhibitors of ocular angiogenesis. <b>2014</b> , 129, 161-71		60
534	Complications of subspecialty ophthalmic care: systemic complications from the intravitreal administration of agents that target the vascular endothelial growth factor pathway. <b>2014</b> , 29, 263-75		7
533	Complications of subspecialty ophthalmic care: endophthalmitis after intravitreal injections of anti-vascular endothelial growth factor medications. <b>2014</b> , 29, 257-62		21
532	Vaccination with a mutated variant of human Vascular Endothelial Growth Factor (VEGF) blocks VEGF-induced retinal neovascularization in a rabbit experimental model. <b>2014</b> , 122, 102-9		7
531	The Adrenergic system as a possible new target for pharmacologic treatment of neovascular retinal diseases. <b>2014</b> , 42, 103-29		46
530	Posterior sub-tenon® bevacizumab injection in diabetic macular edema; a pilot study. <b>2015</b> , 29, 270-3		1
529	Estrogen therapy to treat retinopathy in newborn mice. <b>2015</b> , 10, 611-617		2
528	Encyclopedia of Ophthalmology. <b>2015</b> , 1-8		
527	Intravitreal Injection--Technique and Safety. <b>2015</b> , 4, 321-8		32
526	The effect of normal aging and age-related macular degeneration on perceptual learning. <b>2015</b> , 15, 16		16

525	Stereotactic radiotherapy for wet age-related macular degeneration: current perspectives. <b>2015</b> , 9, 1829-34	7
524	Intravitreal administration of bevacizumab: pros and cons. <b>2015</b> , 23, 27	2
523	Aflibercept: A Review of Its Use in Diabetic Macular Oedema. <b>2015</b> , 75, 1153-60	4
522	A lipidomic screen of hyperglycemia-treated HRECs links 12/15-Lipoxygenase to microvascular dysfunction during diabetic retinopathy via NADPH oxidase. <b>2015</b> , 56, 599-611	46
521	Monitoring VEGF levels with low-volume sampling in major vision-threatening diseases: age-related macular degeneration and diabetic retinopathy. <b>2015</b> , 15, 2357-63	19
520	A systematic review and meta-analysis comparing intravitreal ranibizumab with bevacizumab for the treatment of myopic choroidal neovascularisation. <b>2015</b> , 29, 147-55	4
519	Incidence of myocardial infarction, stroke, and death in patients with age-related macular degeneration treated with intravitreal anti-vascular endothelial growth factor therapy. <b>2015</b> , 159, 557-64.e1	25
518	Endophthalmitis after resident-performed intravitreal bevacizumab injection. <b>2015</b> , 50, 33-6	19
517	Novel Nrf2 activators from microbial transformation products inhibit blood-retinal barrier permeability in rabbits. <b>2015</b> , 172, 1237-49	21
516	Comparative safety and tolerability of anti-VEGF therapy in age-related macular degeneration. <b>2015</b> , 38, 279-93	15
515	Therapeutic Potential of Anti-Angiogenic Multitarget N,O-Sulfated E. Coli K5 Polysaccharide in Diabetic Retinopathy. <b>2015</b> , 64, 2581-92	17
514	Intravitreal injections: What do patients prefer? Analysis of patient satisfaction and preferences about where to perform intravitreal injection. Author reply. <b>2015</b> , 90, 295-6	
513	Intravitreal injections: What do patients prefer? Analysis of patient satisfaction and preferences about where to perform intravitreal injection. Author reply. <b>2015</b> , 90, 295-296	
512	Ranibizumab and aflibercept for the treatment of wet age-related macular degeneration. <b>2015</b> , 15, 1349-58	16
511	Type 2 diabetes mellitus: limitations of conventional therapies and intervention with nucleic acid-based therapeutics. <b>2015</b> , 115, 4719-43	49
510	The effect of AMA0428, a novel and potent ROCK inhibitor, in a model of neovascular age-related macular degeneration. <b>2015</b> , 56, 1335-48	32
509	Thrombospondin-1-Based Antiangiogenic Therapy. <b>2015</b> , 31, 366-70	6
508	Intravitreal injections for nurse practitioners: A guide to good practice. <b>2015</b> , 6, 2-7	

507	Photokinetic Drug Delivery: Light-Enhanced Permeation in an In Vitro Eye Model. <b>2015</b> , 31, 650-7	1
506	Efficacy of single bevacizumab injection as adjuvant therapy to laser photocoagulation in macular edema secondary to branch retinal vein occlusion. <b>2016</b> , 10, 2135-2140	4
505	Different Ipsi- and Contralateral Glial Responses to Anti-VEGF and Triamcinolone Intravitreal Injections in Rats. <b>2016</b> , 57, 3533-44	18
504	Nanomedicine in the application of uveal melanoma. <b>2016</b> , 9, 1215-25	10
503	Rehabilitation Approaches in Macular Degeneration Patients. <b>2016</b> , 10, 107	13
502	Diabetic Retinopathy Clinical Practice Guidelines: Customized for Iranian Population. <b>2016</b> , 11, 394-414	9
501	Angiogenesis and Inflammation Crosstalk in Diabetic Retinopathy. <b>2016</b> , 117, 2443-53	133
500	The annexin A2 system and angiogenesis. <b>2016</b> , 397, 1005-16	24
499	Effects of commonly used intravitreal anti-vascular endothelial growth factor drugs on mesenchymal stem cells derived from the limbus and ciliary body. <b>2016</b> , 44, 587-596	2
498	Subconjunctival Delivery of Dorzolamide-Loaded Poly(ether-anhydride) Microparticles Produces Sustained Lowering of Intraocular Pressure in Rabbits. <b>2016</b> , 13, 2987-95	30
497	Efficacy of Antibody Delivery to the Retina and Optic Nerve by Topical Administration. <b>2016</b> , 32, 203-10	3
496	Ocular Toxicity of Tyrosine Kinase Inhibitors. <b>2016</b> , 43, 235-43	15
495	HIF inhibitors for ischemic retinopathies and cancers: options beyond anti-VEGF therapies. <b>2016</b> , 19, 257-73	17
494	In vivo and in vitro sustained release of ranibizumab from a nanoporous thin-film device. <b>2016</b> , 6, 771-780	17
493	Study of stability and biophysical characterization of ranibizumab and aflibercept. <b>2016</b> , 108, 156-167	24
492	Intravitreal vascular endothelial growth factor (VEGF) inhibitor injection in unrecognized early pregnancy. <b>2016</b> , 34, 650-3	7
491	Targeting VEGF and Its Receptors for the Treatment of Osteoarthritis and Associated Pain. <b>2016</b> , 31, 911-24	112
490	Light activated liposomes: Functionality and prospects in ocular drug delivery. <b>2016</b> , 244, 157-166	57

489	ANGPTL4- <del>48</del> interaction counteracts hypoxia-induced vascular permeability by modulating Src signalling downstream of vascular endothelial growth factor receptor 2. <b>2016</b> , 240, 461-471		27
488	Glaucoma: the retina and beyond. <b>2016</b> , 132, 807-826		129
487	Anti-VEGF in diabetic retinopathy and diabetic macular edema. <b>2016</b> , 11, 443-451		0
486	Rate of intraoperative complications during cataract surgery following intravitreal injections. <i>Eye</i> , <b>2016</b> , 30, 1101-9	4.4	13
485	A novel small molecule ameliorates ocular neovascularisation and synergises with anti-VEGF therapy. <b>2016</b> , 6, 25509		42
484	Drugs Used in Ocular Treatment. <b>2016</b> , 503-512		
483	Targeting MAPK Signaling in Age-Related Macular Degeneration. <b>2016</b> , 8, 23-30		31
482	Diosmetin protects against retinal injury via reduction of DNA damage and oxidative stress. <b>2016</b> , 3, 78-86		10
481	Targeting VEGF in eye neovascularization: What's new?: A comprehensive review on current therapies and oligonucleotide-based interventions under development. <b>2016</b> , 103, 253-69		106
480	A multimodal approach to diabetic macular edema. <b>2016</b> , 30, 545-53		10
479	Fit for the Eye: Aptamers in Ocular Disorders. <b>2016</b> , 26, 127-46		77
478	Cytotoxicity assessment of porous silicon microparticles for ocular drug delivery. <b>2016</b> , 100, 1-8		30
477	Anti-angiogenic and anti-inflammatory effect of Magnolol in the oxygen-induced retinopathy model. <b>2016</b> , 65, 81-93		23
476	Safety of monoclonal antibodies and related therapeutic proteins for the treatment of neovascular macular degeneration: addressing outstanding issues. <b>2016</b> , 15, 75-87		8
475	Effect of Prior Anti-VEGF Injections on the Risk of Retained Lens Fragments and Endophthalmitis after Cataract Surgery in the Elderly. <b>2016</b> , 123, 309-315		26
474	Fenestrated microneedles for ocular drug delivery. <b>2016</b> , 223, 15-23		35
473	AMA0428, A Potent ROCK Inhibitor, Attenuates Early and Late Experimental Diabetic Retinopathy. <b>2017</b> , 42, 260-272		22
472	Gene therapy for diabetic retinopathy: Are we ready to make the leap from bench to bedside?. <b>2017</b> , 173, 1-18		25

471	Switching from pro re nata to treat-and-extend regimen improves visual acuity in patients with neovascular age-related macular degeneration. <b>2017</b> , 95, 678-682	33
470	Vision Preservation in Eyes of Polypoidal Choroidal Vasculopathy with Low-Dose Intravitreal Triamcinolone Acetonide. <b>2017</b> , 33, 42-49	2
469	Suprachoroidal haemorrhage following intravitreal injection. <b>2017</b> , 93, 56	1
468	Vascular endothelial growth factor-Ab ameliorates outer-retinal barrier and vascular dysfunction in the diabetic retina. <b>2017</b> , 131, 1225-1243	30
467	Acute angle closure attack after an intravitreal bevacizumab injection for branch retinal vein occlusion: a case report. <b>2017</b> , 17, 25	6
466	Recent drug therapies for corneal neovascularization. <b>2017</b> , 90, 653-664	12
465	A safety study of high concentration and high frequency intravitreal injection of conbercept in rabbits. <b>2017</b> , 7, 592	10
464	Microfluidic co-cultures of retinal pigment epithelial cells and vascular endothelial cells to investigate choroidal angiogenesis. <b>2017</b> , 7, 3538	51
463	All-trans retinoic acid upregulates the expression of ciliary neurotrophic factor in retinal pigment epithelial cells. <b>2017</b> , 35, 202-208	2
462	Vision Loss after Intravitreal Injection of Autologous "Stem Cells" for AMD. <b>2017</b> , 376, 1047-1053	254
461	Generation and characterization of ABBV642, a dual variable domain immunoglobulin molecule (DVD-Ig) that potently neutralizes VEGF and PDGF-BB and is designed for the treatment of exudative age-related macular degeneration. <b>2017</b> , 9, 269-284	11
460	Treatment patterns of ranibizumab intravitreal injection and dexamethasone intravitreal implant for retinal vein occlusion in the USA. <i>Eye</i> , <b>2017</b> , 31, 551-559	4-4 8
459	How are we improving the delivery to back of the eye? Advances and challenges of novel therapeutic approaches. <b>2017</b> , 14, 1145-1162	28
458	Resveratrol reverses the adverse effects of bevacizumab on cultured ARPE-19 cells. <b>2017</b> , 7, 12242	16
457	Neovascular Age-Related Macular Degeneration Disease Quiescence with Visual Acuity Stability in a Subgroup of Patients Following PRN Treatment. <b>2017</b> , 33, 604-609	3
456	Homoisoflavonoids as potential antiangiogenic agents for retinal neovascularization. <b>2017</b> , 95, 818-827	8
455	Discerning the composition of penetratin for safe penetration from cornea to retina. <b>2017</b> , 63, 123-134	15
454	Aged macular degeneration: current therapeutics for management and promising new drug candidates. <b>2017</b> , 22, 1671-1679	19

453	Vascular Endothelial Growth Factor and Ischemic Heart Disease Risk: A Mendelian Randomization Study. <b>2017</b> , 6,	11
452	Introduction of a nurse-led intravitreal injection service in ophthalmology. <b>2017</b> , 26, 800-803	6
451	Hot Topics in Pharmacotherapy for Neovascular Age-Related Macular Degeneration. <b>2017</b> , 23, 535-541	5
450	An apelin receptor antagonist prevents pathological retinal angiogenesis with ischemic retinopathy in mice. <b>2017</b> , 7, 15062	16
449	Modulating release of ranibizumab and aflibercept from thiolated chitosan-based hydrogels for potential treatment of ocular neovascularization. <b>2017</b> , 14, 913-925	19
448	Aptamers as targeted therapeutics: current potential and challenges. <b>2017</b> , 16, 181-202	822
447	Minimally invasive microneedles for ocular drug delivery. <b>2017</b> , 14, 525-537	61
446	Diabetic macular oedema. <b>2017</b> , 5, 143-155	127
445	Electrospun Scaffold for Retinal Tissue Engineering. <b>2017</b> , 235-250	
444	Topical Delivery of Anti-VEGF Drugs to the Ocular Posterior Segment Using Cell-Penetrating Peptides. <b>2017</b> , 58, 2578-2590	44
443	Potential Diagnostic and Therapeutic Applications of Oligonucleotide Aptamers in Breast Cancer. <b>2017</b> , 18,	19
442	EGHB010, a Standardized Extract of Paeoniae Radix and Glycyrrhizae Radix, Inhibits VEGF-Induced Tube Formation In Vitro and Retinal Vascular Leakage and Choroidal Neovascularization In Vivo. <b>2017</b> , 2017, 1568702	3
441	Aspalatone Prevents VEGF-Induced Lipid Peroxidation, Migration, Tube Formation, and Dysfunction of Human Aortic Endothelial Cells. <b>2017</b> , 2017, 2769347	10
440	Decoding Noncoding RNAs: Role of MicroRNAs and Long Noncoding RNAs in Ocular Neovascularization. <b>2017</b> , 7, 3155-3167	26
439	Sustaining Intravitreal Residence With L-Arginine Peptide-Conjugated Nanocarriers. <b>2017</b> , 58, 5142-5150	10
438	Neovascular (Wet) Age-Related Macular Degeneration. <b>2017</b> , 89-116	0
437	Effect of oral tranexamic acid on macular edema associated with retinal vein occlusion or diabetes. <b>2018</b> , 12, 35-41	2
436	Adiponectin Mediates Dietary Omega-3 Long-Chain Polyunsaturated Fatty Acid Protection Against Choroidal Neovascularization in Mice. <b>2017</b> , 58, 3862-3870	16

435	Targeted Delivery of FLT-Morpholino Using Cyclic RGD Peptide. <b>2017</b> , 6, 9	1
434	Ocular drug delivery targeted by iontophoresis in the suprachoroidal space using a microneedle. <b>2018</b> , 277, 14-22	47
433	Photokinetic Drug Delivery: Near infrared (NIR) Induced Permeation Enhancement of Bevacizumab, Ranibizumab and Aflibercept through Human Sclera. <b>2018</b> , 35, 110	6
432	Incidence of endophthalmitis after intravitreal injections at a tertiary care hospital. <b>2018</b> , 53, 94-97	6
431	The Discovery of N-(1-Methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl)-5-((6-((methylamino)methyl)pyrimidin-4-yl)oxy)-1H-indole-1-carboxamide (Acrizanib), a VEGFR-2 Inhibitor Specifically Designed for Topical Ocular Delivery, as a Therapy for Neovascular Age-Related Macular Degeneration. <b>2018</b> , 61, 1622-1635	13
430	CHANGES IN PLASMA VASCULAR ENDOTHELIAL GROWTH FACTOR LEVEL AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB, AFLIBERCEPT, OR RANIBIZUMAB FOR DIABETIC MACULAR EDEMA. <b>2018</b> , 38, 1801-1808	24
429	AAV-mediated gene delivery of the calreticulin anti-angiogenic domain inhibits ocular neovascularization. <b>2018</b> , 21, 95-109	8
428	Removal of choroidal neovascular membrane in a case of macular hole after anti-VEGF therapy for age-related macular degeneration. <b>2018</b> , 9, 14-17	7
427	Changing vision: a review of pharmacogenetic studies for treatment response in age-related macular degeneration patients. <b>2018</b> , 19, 435-461	4
426	Safety and efficacy of intravitreal injection of steroid and antibiotics in the setting of cataract surgery and trabecular microbypass stent. <b>2018</b> , 44, 56-62	4
425	Placental growth factor and its potential role in diabetic retinopathy and other ocular neovascular diseases. <b>2018</b> , 96, e1-e9	45
424	Nanocarrier mediated retinal drug delivery: overcoming ocular barriers to treat posterior eye diseases. <b>2018</b> , 10, e1473	47
423	Ocular tissue distribution and pharmacokinetic study of a small 13kDa domain antibody after intravitreal, subconjunctival and eye drop administration in rabbits. <b>2018</b> , 167, 14-17	4
422	Preclinical Evaluation and Optimization of a Cell Therapy Using Human Cord Blood-Derived Endothelial Colony-Forming Cells for Ischemic Retinopathies. <b>2018</b> , 7, 59-67	23
421	Chemical Proteomics Reveals Soluble Epoxide Hydrolase as a Therapeutic Target for Ocular Neovascularization. <b>2018</b> , 13, 45-52	16
420	Evolving multidimensional pharmacological approaches to CNV therapy in AMD. <b>2018</b> , 43, 147-154	6
419	. <b>2018</b> ,	0
418	Rapid Progression of the Epiretinal Membrane after Intravitreal Aflibercept Injection. <b>2018</b> , 59, 984	



417	Role of topical antibiotics in prophylaxis against endophthalmitis following intravitreal antibiotics. <b>2018</b> , 34, 1283-1287	2
416	Self-implantable double-layered micro-drug-reservoirs for efficient and controlled ocular drug delivery. <b>2018</b> , 9, 4433	127
415	Leukotriene B4 promotes neovascularization and macrophage recruitment in murine wet-type AMD models. <b>2018</b> , 3,	21
414	The Different Facades of Retinal and Choroidal Endothelial Cells in Response to Hypoxia. <b>2018</b> , 19,	21
413	Molecular Mechanisms Mediating Diabetic Retinal Neurodegeneration: Potential Research Avenues and Therapeutic Targets. <b>2018</b> , 66, 445-461	13
412	A Small Molecule TrkB Neurotrophin Receptor Partial Agonist as Possible Treatment for Experimental Nonarteritic Anterior Ischemic Optic Neuropathy. <b>2018</b> , 43, 1489-1499	6
411	Depthwise-controlled scleral insertion of microneedles for drug delivery to the back of the eye. <b>2018</b> , 133, 31-41	18
410	Effect of nanoencapsulation using poly (lactide-co-glycolide) (PLGA) on anti-angiogenic activity of bevacizumab for ocular angiogenesis therapy. <b>2018</b> , 107, 1056-1063	27
409	Novel Random Triblock Copolymers for Sustained Delivery of Macromolecules for the Treatment of Ocular Diseases. <b>2018</b> , 19, 3871-3885	1
408	Thermoresponsive Gel Drug Delivery for Retina and Posterior Segment Disease. <b>2018</b> , 397-409	1
407	Gene Therapy for Inherited Retinopathies: Update on Development Progress. <b>2018</b> , 2, 219-226	
406	Synthesis of magnetite (Fe <sub>3</sub> O <sub>4</sub> )Avastin nanocomposite as a potential drug for AMD treatment. <b>2018</b> , 13, 1141-1145	1
405	Noninfectious Inflammatory Response following Intravitreal Bevacizumab Injections: Description of a Cluster of Cases in Two Centers and a Review of the Literature. <b>2018</b> , 240, 163-166	6
404	A review on recent drug delivery systems for posterior segment of eye. <b>2018</b> , 107, 1564-1582	91
403	Extended Intravitreal Rabbit Eye Residence of Nanoparticles Conjugated With Cationic Arginine Peptides for Intraocular Drug Delivery: In Vivo Imaging. <b>2018</b> , 59, 4071-4081	8
402	NCK-dependent pericyte migration promotes pathological neovascularization in ischemic retinopathy. <b>2018</b> , 9, 3463	36
401	Targeted Drug Delivery in the Suprachoroidal Space by Swollen Hydrogel Pushing. <b>2018</b> , 59, 2069-2079	23
400	Characterization of Site-Specific Phosphorylation of NF- $\kappa$ B p65 in Retinal Cells in Response to High Glucose and Cytokine Polarization. <b>2018</b> , 2018, 3020675	17

399	The route of administration influences the therapeutic index of an anti-proNGF neutralizing mAb for experimental treatment of Diabetic Retinopathy. <b>2018</b> , 13, e0199079	9
398	Microneedles for Ocular Drug Delivery and Targeting: Challenges and Opportunities. <b>2018</b> , 283-306	2
397	Extract and Chlorogenic Acid Inhibit Retinal Angiogenesis in a Mouse Model of Oxygen-Induced Retinopathy. <b>2018</b> , 2018, 6402650	10
396	Rapid "epiretinal membrane" development following intravitreal bevacizumab for Coats Disease. <b>2018</b> , 11, 75-77	3
395	Quantitative biometry of zebrafish retinal vasculature using optical coherence tomographic angiography. <b>2018</b> , 9, 1244-1255	8
394	Bevacizumab Diminishes Inflammation in an Acute Endotoxin-Induced Uveitis Model. <b>2018</b> , 9, 649	6
393	7.1 T MRI and T2 mapping of the human and porcine vitreous body post mortem. <b>2018</b> , 131, 82-91	5
392	Intraocular Penetration of a vNAR: In Vivo and In Vitro VEGF Neutralization. <b>2018</b> , 16,	15
391	Development of an inducible anti-VEGF rAAV gene therapy strategy for the treatment of wet AMD. <b>2018</b> , 8, 11763	25
390	Ref-1/APE1 Inhibition with Novel Small Molecules Blocks Ocular Neovascularization. <b>2018</b> , 367, 108-118	15
389	Subretinal macrophages produce classical complement activator C1q leading to the progression of focal retinal degeneration. <b>2018</b> , 13, 45	20
388	BMP9 (Bone Morphogenetic Protein-9)/Alk1 (Activin-Like Kinase Receptor Type I) Signaling Prevents Hyperglycemia-Induced Vascular Permeability. <b>2018</b> , 38, 1821-1836	31
387	Pro- and antiangiogenic therapies: current status and clinical implications. <b>2019</b> , 33, 34-48	28
386	Three patients with injection of intravitreal vascular endothelial growth factor inhibitors and subsequent exacerbation of chronic proteinuria and hypertension. <b>2019</b> , 12, 92-100	25
385	Safety of 5914 intravitreal ziv-aflibercept injections. <b>2019</b> , 103, 805-810	20
384	Advances in the treatment of diabetic retinopathy. <b>2019</b> , 33, 107417	27
383	Enantioselective Synthesis of Homoisoflavanones by Asymmetric Transfer Hydrogenation and Their Biological Evaluation for Antiangiogenic Activity. <b>2019</b> , 84, 9995-10011	9
382	Hollow Microcapsules as Periocular Drug Depot for Sustained Release of Anti-VEGF Protein. <b>2019</b> , 11,	4

381	Self-Assembling Topical Nanomicellar Formulation to Improve Curcumin Absorption Across Ocular Tissues. <b>2019</b> , 20, 254	15
380	Intravitreal Ziv-Aflibercept: A Comprehensive Review. <b>2019</b> , 34, 420-435	6
379	Apratoxin S4 Inspired by a Marine Natural Product, a New Treatment Option for Ocular Angiogenic Diseases. <b>2019</b> , 60, 3254-3263	6
378	Supramolecular cyclodextrin complex: Diversity, safety, and applications in ocular therapeutics. <b>2019</b> , 189, 107829	21
377	A comparison in precision and accuracy of the conventional syringe to the Suh precision syringe. <b>2019</b> , 13, 1833-1839	
376	Extended release of dexamethasone from oleogel based rods. <b>2019</b> , 555, 331-341	12
375	Adult Stem Cell Therapeutics in Diabetic Retinopathy. <b>2019</b> , 20,	15
374	Ischaemic colitis associated with intravitreal administration of aflibercept: A first case report. <b>2019</b> , 85, 845-848	5
373	Hypotensive efficacy of topical brimonidine for intraocular pressure spikes following intravitreal injections of antivascular endothelial growth factor agents: a randomised crossover trial. <b>2019</b> , 103, 1388-1394 <sup>4</sup>	
372	Suprachoroidally injected pharmacological agents for the treatment of chorio-retinal diseases: a targeted approach. <b>2019</b> , 97, 460-472	30
371	Characterization of Biodegradable Microsphere-Hydrogel Ocular Drug Delivery System for Controlled and Extended Release of Ranibizumab. <b>2019</b> , 8, 12	29
370	Human Herpesvirus-6 corneal Endotheliitis after intravitreal injection of Ranibizumab. <b>2019</b> , 19, 19	4
369	Topical sustained drug delivery to the retina with a drug-eluting contact lens. <b>2019</b> , 217, 119285	47
368	Endophilin-A2 dependent VEGFR2 endocytosis promotes sprouting angiogenesis. <b>2019</b> , 10, 2350	34
367	The leukotriene receptors as therapeutic targets of inflammatory diseases. <b>2019</b> , 31, 607-615	30
366	Hydrogel implants for transscleral drug delivery for retinoblastoma treatment. <b>2019</b> , 103, 109799	14
365	Drug micro-carriers with a hyaluronic acid corona toward a diffusion-limited aggregation within the vitreous body. <b>2019</b> , 220, 185-190	9
364	Elevation of the vitreous body concentrations of oxidative stress-responsive apoptosis-inducing protein (ORAIP) in proliferative diabetic retinopathy. <b>2019</b> , 257, 1519-1525	4

363	Liposomes for effective drug delivery to the ocular posterior chamber. <b>2019</b> , 17, 64	39
362	Modulation of the p75 neurotrophin receptor using LM11A-31 prevents diabetes-induced retinal vascular permeability in mice via inhibition of inflammation and the RhoA kinase pathway. <b>2019</b> , 62, 1488-1500 <sup>16</sup>	
361	Real-World Trends in Intravitreal Injection Practices among American Retina Specialists. <b>2019</b> , 3, 656-662	11
360	A review on recent advancements in ophthalmology devices: Currently in market and under clinical trials. <b>2019</b> , 52, 334-345	7
359	Wheat alkylresorcinols protect human retinal pigment epithelial cells against HO-induced oxidative damage through Akt-dependent Nrf2/HO-1 signaling. <b>2019</b> , 10, 2797-2804	17
358	Repeated retinal photocoagulation in monkeys for the optimization of a laser-induced choroidal neovascularization model. <b>2019</b> , 184, 1-7	4
357	VEGF inhibition alters neurotrophin signalling pathways and induces caspase-3 activation and autophagy in rabbit retina. <b>2019</b> , 234, 18297-18307	8
356	Aflibercept: A review of its effect on the treatment of exudative age-related macular degeneration. <b>2019</b> , 29, 368-378	14
355	Real-world outcomes of observation and treatment in diabetic macular edema with very good visual acuity: the OBTAIN study. <b>2019</b> , 56, 777-784	9
354	Molecular-Physiological Aspects of Regulatory Effect of Peptide Retinoprotectors. <b>2019</b> , 15, 439-442	3
353	Efficacy and safety of intravitreal drug injections using a short 34-gauge needle. <b>2019</b> , 63, 269-275	2
352	Intravenous injection of l-aspartic acid hydroxamate attenuates choroidal neovascularization via anti-VEGF and anti-inflammation. <b>2019</b> , 182, 93-100	3
351	Vision loss after chemotherapy: an irinotecan-induced retinopathy. <b>2019</b> , 112, 80-82	2
350	The Antiangiogenic Activity of Naturally Occurring and Synthetic Homoisoflavonoids from the Hyacinthaceae (sensu APGII). <b>2019</b> , 82, 1227-1239	7
349	Dietary Polyphenols in Age-Related Macular Degeneration: Protection against Oxidative Stress and Beyond. <b>2019</b> , 2019, 9682318	40
348	Targeting drug delivery within the suprachoroidal space. <b>2019</b> , 24, 1654-1659	12
347	Soluble Epoxide Hydrolase Inhibition for Ocular Diseases: Vision for the Future. <b>2019</b> , 10, 95	12
346	KC21 Peptide Inhibits Angiogenesis and Attenuates Hypoxia-Induced Retinopathy. <b>2019</b> , 12, 366-377	2

345	Intravenous treatment of choroidal neovascularization by photo-targeted nanoparticles. <b>2019</b> , 10, 804	39
344	Combining Visual Cleansing and Exploration for Clinical Data. <b>2019</b> ,	1
343	Paper-Based ELISA: A Novel Diagnostic Approach for Monitoring Aqueous Humour VEGF Level in Ocular Diseases. <b>2019</b> ,	1
342	Repeated intravitreal injections of anti-vascular endothelial growth factor in patients with neovascular age-related macular degeneration may increase the risk of ischemic optic neuropathy. <b>2019</b> , 19, 268	5
341	Nanoscale delivery systems in treatment of posterior ocular neovascularization: strategies and potential applications. <b>2019</b> , 10, 737-747	4
340	Characteristics and Outcomes of Full-thickness Macular Hole Repair in Patients Receiving Anti-VEGF Injections for Neovascular Age-related Macular Degeneration. <b>2019</b> , 59, 127-135	1
339	Long-term outcome of using Prosthetic Replacement of Ocular Surface Ecosystem (PROSE) as a drug delivery system for bevacizumab in the treatment of corneal neovascularization. <b>2019</b> , 17, 134-141	10
338	Nanofluidic microsystem for sustained intraocular delivery of therapeutics. <b>2019</b> , 16, 1-9	24
337	Epithelial Membrane Protein-2 (EMP2) Antibody Blockade Reduces Corneal Neovascularization in an In Vivo Model. <b>2019</b> , 60, 245-254	8
336	Experiences and perceptions of patients undergoing treatment and quality of life impact of diabetic macular edema: a systematic review. <b>2019</b> , 24, 383-401	4
335	Management of Diabetes Mellitus. <b>2019</b> , 113-177	
334	In Vivo Stability Profiles of Anti-factor D Molecules Support Long-Acting Delivery Approaches. <b>2019</b> , 16, 86-95	1
333	Biodegradable Microsphere-Hydrogel Ocular Drug Delivery System for Controlled and Extended Release of Bioactive Aflibercept In Vitro. <b>2019</b> , 44, 264-274	39
332	In situ forming phase-inversion implants for sustained ocular delivery of triamcinolone acetonide. <b>2019</b> , 9, 534-542	19
331	Surgical and Nonsurgical Trauma. <b>2020</b> , 102-162.e6	
330	Pericytes, inflammation, and diabetic retinopathy. <b>2020</b> , 28, 697-709	23
329	Amphiphilic additives in silicone oil tamponade and emulsification: an eye-on-a-chip study. <b>2020</b> , 98, e232-e2374	
328	Endophthalmitis after intravitreal injections versus cataract surgery: a 15-year cohort. <b>2020</b> , 40, 73-79	5

327	Brivanib, a multitargeted small-molecule tyrosine kinase inhibitor, suppresses laser-induced CNV in a mouse model of neovascular AMD. <b>2020</b> , 235, 1259-1273	9
326	Intravitreal Ziv-Aflibercept : Safety Analysis in Eyes Receiving More Than Ten Intravitreal Injections. <b>2020</b> , 35, 2-6	8
325	The Short-Term Efficacy of Biweekly Subconjunctival Bevacizumab in Diabetic Macular Edema. <b>2020</b> , 45, 585-590	0
324	Long-Term Follow-Up Changes of Central Choroidal Thickness Thinning after Repeated Anti-VEGF Therapy Injections in Patients with Central Retinal Vein Occlusion-Related Macular Edema with Systemic Hypertension. <b>2020</b> , 243, 102-109	3
323	Systemic Administration of an Apelin Receptor Agonist Prevents NMDA-Induced Loss of Retinal Neuronal Cells in Mice. <b>2020</b> , 45, 752-759	6
322	SUSPENDING TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN CASES OF FUTILITY. <b>2020</b> , 40, 1010-1020	5
321	Local delivery of corticosteroids in clinical ophthalmology: A review. <b>2020</b> , 48, 366-401	18
320	Biotechnology and Biomaterial-Based Therapeutic Strategies for Age-Related Macular Degeneration. Part I: Biomaterials-Based Drug Delivery Devices. <b>2020</b> , 8, 549089	3
319	Reporting of Safety Events during Anti-VEGF Treatment: Pharmacovigilance in a Noninterventional Trial. <b>2020</b> , 2020, 8652370	3
318	Neuroprotective effect of melatonin loaded in ethylcellulose nanoparticles applied topically in a retinal degeneration model in rabbits. <b>2020</b> , 200, 108222	11
317	Densitometric analysis of cornea in patients with neovascular age-related macular degeneration after intravitreal aflibercept loading dose. <b>2020</b> , 12, 2515841420950857	2
316	Ilimaquinone inhibits neovascular age-related macular degeneration through modulation of Wnt/βcatenin and p53 pathways. <b>2020</b> , 161, 105146	2
315	Molecular Mechanisms of Retina Pathology and Ways of its Correction. <b>2020</b> ,	
314	Literature Review. <b>2020</b> , 1-42	
313	Dosimetry modeling of focused kV x-ray radiotherapy for wet age-related macular degeneration. <b>2020</b> , 47, 5123-5134	
312	Preclinical and clinical studies of photobiomodulation therapy for macular oedema. <b>2020</b> , 63, 1900-1915	5
311	Laquinimod Inhibits Inflammation-Induced Angiogenesis in the Cornea. <b>2020</b> , 7, 598056	2
310	Survey of Intravitreal Injection Techniques Among Retina Specialists in Mexico. <b>2020</b> , 14, 4089-4098	

309	Clinical and Molecular-Genetic Insights into the Role of Oxidative Stress in Diabetic Retinopathy: Antioxidant Strategies and Future Avenues. <b>2020</b> , 9,	5
308	The effects of intravitreal injections on intraocular pressure and retinal nerve fiber layer: a systematic review and meta-analysis. <b>2020</b> , 10, 13248	14
307	Bradykinin 1 Receptor Antagonist BI1026706 Does Not Reduce Central Retinal Thickness in Center-Involved Diabetic Macular Edema. <b>2020</b> , 9, 25	1
306	Structure-Guided Molecular Engineering of a Vascular Endothelial Growth Factor Antagonist to Treat Retinal Diseases. <b>2020</b> , 13, 405-418	0
305	Therapeutic Interventions into Innate Immune Diseases by Means of Aptamers. <b>2020</b> , 12,	3
304	An allosteric peptide inhibitor of HIF-1 $\beta$ regulates hypoxia-induced retinal neovascularization. <b>2020</b> , 117, 28297-28306	8
303	Recent Developments in the Treatment of Wet Age-related Macular Degeneration. <b>2020</b> , 40, 851-857	3
302	Injectables and Depots to Prolong Drug Action of Proteins and Peptides. <b>2020</b> , 12,	11
301	Acute Angle-Closure Glaucoma Secondary to Vitreous Hemorrhage Diagnosed with the Aid of Point-of-Care Ultrasound. <b>2020</b> , 59, e235-e237	
300	Dual-Acting Antiangiogenic Gene Therapy Reduces Inflammation and Regresses Neovascularization in Diabetic Mouse Retina. <b>2020</b> , 22, 329-339	2
299	Differential reperfusion patterns in retinal vascular plexuses following increase in intraocular pressure an OCT angiography study. <b>2020</b> , 10, 16505	4
298	A Preliminary Study of Predicting Effectiveness of Anti-VEGF Injection Using OCT Images Based on Deep Learning. <b>2020</b> , 2020, 5428-5431	5
297	Safety and tolerability evaluation after repeated intravitreal injections of a humanized anti-VEGF-A monoclonal antibody (PRO-169) versus ranibizumab in New Zealand white rabbits. <b>2020</b> , 6, 32	2
296	Errors in prescription and volume administration during intravitreal injection of ophthalmic medications: Time to change prescribing practice?. <b>2020</b> , 1120672120965511	1
295	Ophthalmic Drops with Nanoparticles Derived from a Natural Product for Treating Age-Related Macular Degeneration. <b>2020</b> , 12, 57710-57720	2
294	Topical delivery of a small molecule RUNX1 transcription factor inhibitor for the treatment of proliferative vitreoretinopathy. <b>2020</b> , 10, 20554	9
293	Small-Molecule Modulation of PPARs for the Treatment of Prevalent Vascular Retinal Diseases. <b>2020</b> , 21,	3
292	Treatment Efficacy and Biocompatibility of a Biodegradable Aflibercept-Loaded Microsphere-Hydrogel Drug Delivery System. <b>2020</b> , 9, 13	4

291	Subthreshold micropulse yellow laser for the management of refractory cystoid macular edema consequent to complicated cataract surgery. <b>2021</b> , 31, NP93-NP98	0
290	Intravitreal Injections in Arc Sterile Setting: Safety Profile after More Than 10,000 Treatments. <b>2020</b> , 2020, 3680406	2
289	Complete RPE and outer retinal atrophy in patients receiving anti-VEGF treatment for neovascular age-related macular degeneration. <b>2020</b> , 15, e0232353	5
288	Chitosan-Polycaprolactone Core-Shell Microparticles for Sustained Delivery of Bevacizumab. <b>2020</b> , 17, 2570-2584	16
287	Characterization of Polymeric Syringes Used for Intravitreal Injection. <b>2020</b> , 109, 2812-2818	1
286	Drug Delivery to the Posterior Segment of the Eye: Biopharmaceutic and Pharmacokinetic Considerations. <b>2020</b> , 12,	89
285	Focused ultrasound as a novel strategy for noninvasive gene delivery to retinal Müller glia. <b>2020</b> , 10, 2982-2999	7
284	MicroRNA-18a-5p Administration Suppresses Retinal Neovascularization by Targeting FGF1 and HIF1A. <b>2020</b> , 11, 276	7
283	High Density Display of an Anti-Angiogenic Peptide on Micelle Surfaces Enhances Their Inhibition of $\alpha_5\beta_1$ Integrin-Mediated Neovascularization In Vitro. <b>2020</b> , 10,	6
282	Noble Metals and Soft Bio-Inspired Nanoparticles in Retinal Diseases Treatment: A Perspective. <b>2020</b> , 9,	20
281	Iatrogenic ophthalmic artery occlusion and retinal artery occlusion. <b>2020</b> , 100848	9
280	Therapeutic Potential of the Ranibizumab Port Delivery System in the Treatment of AMD: Evidence to Date. <b>2020</b> , 14, 1349-1355	18
279	Effect of Repeated Intravitreal Ranibizumab and Aflibercept Injections on the Cornea in Patients with Age-Related Macular Degeneration. <b>2020</b> , 2020, 4928905	1
278	Investigating the Role of PPAR $\gamma$ in Retinal Vascular Remodeling Using $\gamma$ -Deficient Mice. <b>2020</b> , 21,	3
277	Experimental Models in Neovascular Age Related Macular Degeneration. <b>2020</b> , 21,	6
276	Ursodeoxycholic Acid Halts Pathological Neovascularization in a Mouse Model of Oxygen-Induced Retinopathy. <b>2020</b> , 9,	1
275	extract inhibits retinal neovascularization in a mouse model of oxygen-induced retinopathy, with its bioactive components preventing VEGF-induced retinal vascular hyperpermeability. <b>2020</b> , 8, 2895-2903	1
274	Updates on the Management of Ocular Vasculopathies with VEGF Inhibitor Conbercept. <b>2020</b> , 45, 1467-1476	3



273	Risk of posterior capsular rupture during phacoemulsification cataract surgery in eyes with previous intravitreal anti-vascular endothelial growth factor injections. <b>2020</b> , 46, 204-208	5
272	Dexamethasone 0.4mg Sustained-Release Intracanalicular Insert in the Management of Ocular Inflammation and Pain Following Ophthalmic Surgery: Design, Development and Place in Therapy. <b>2020</b> , 14, 89-94	7
271	Keratocytes promote corneal neovascularization through VEGFR3 induced by PPAR $\gamma$ inhibition. <b>2020</b> , 193, 107982	4
270	Predictive factors of outcome of selective retina therapy for diabetic macular edema. <b>2020</b> , 40, 1221-1232	4
269	Anti-angiogenesis by dual action of R5K peptide conjugated itraconazole nanoparticles. <b>2020</b> , 21, 74	9
268	Oral Delivery of a Tetrameric Tripeptide Inhibitor of VEGFR1 Suppresses Pathological Choroid Neovascularization. <b>2020</b> , 21,	4
267	The Role of Subthreshold Micropulse Yellow Laser as an Alternative Option for the Treatment of Refractory Postoperative Cystoid Macular Edema. <b>2020</b> , 9,	2
266	Can Vitreous Reflux Affect The Short-Term Treatment Response After Intravitreal Ranibizumab Injection?. <b>2021</b> , 46, 248-254	
265	Posterior Capsule Rupture during Cataract Surgery in Eyes Receiving Intravitreal anti-VEGF Injections. <b>2021</b> , 46, 179-184	4
264	Rhegmatogenous Retinal Detachment after Intravitreal Injection. <b>2021</b> , 5, 178-183	0
263	Nanomedicine Approaches to Negotiate Local Biobarriers for Topical Drug Delivery. <b>2021</b> , 4, 2000160	1
262	Hydrogel eye drops as a non-invasive drug carrier for topical enhanced Adalimumab permeation and highly efficient uveitis treatment. <b>2021</b> , 253, 117216	4
261	Polymeric nanomicelles based on inulin D- $\alpha$ -tocopherol succinate for the treatment of diabetic retinopathy. <b>2021</b> , 61, 102286	5
260	Ciliary body length revisited by anterior segment optical coherence tomography: implications for safe access to the pars plana for intravitreal injections. <b>2021</b> , 259, 1435-1441	0
259	Choroidal Detachment following an Intravitreal Injection in a Patient with Vogt-Koyanagi- Harada Disease. <b>2021</b> , 29, 396-398	0
258	Effects of Intravitreal Injection on Ocular Surface and Anterior Segment Parameters.. <b>2021</b> , 6, 84-89	0
257	Mingjing granule, a traditional Chinese medicine in the treatment of neovascular age-related macular degeneration: study protocol for a randomized controlled trial. <b>2021</b> , 22, 69	0
256	Endophthalmitis following Intravitreal Anti-Vascular Endothelial Growth Factor Therapy: Changes in Incidence and Outcomes over a 9-Year Period. <b>2021</b> , 46, 1370-1377	5

255	Distribution of polymeric nanoparticles in the eye: implications in ocular disease therapy. <b>2021</b> , 19, 10	12
254	The interplay of oxidative stress and ARMS2-HTRA1 genetic risk in neovascular AMD. <b>2021</b> , 5,	1
253	Mesenchymal Stromal Cells Promote Retinal Vascular Repair by Modulating Sema3E and IL-17A in a Model of Ischemic Retinopathy. <b>2021</b> , 9, 630645	3
252	Anti-vascular endothelial growth factor in the management of retinopathy of prematurity: A survey among the members of Indian Retinopathy of Prematurity Society. <b>2021</b> , 69, 2158-2163	0
251	Redox-Responsive Hyaluronic Acid-Based Nanogels for the Topical Delivery of the Visual Chromophore to Retinal Photoreceptors. <b>2021</b> , 6, 6172-6184	5
250	Lymphocytic microparticles suppress retinal angiogenesis via targeting Müller cells in the ischemic retinopathy mouse model. <b>2021</b> , 399, 112470	2
249	Case Report: Acute Retinal Necrosis after Intravitreal Ranibizumab for Exudative Macular Degeneration. <b>2021</b> , 98, 206-211	0
248	Nanoparticle-Hydrogel Composite Drug Delivery System for Potential Ocular Applications. <b>2021</b> , 13,	4
247	Corneal endothelial alterations in patients with diabetic macular edema. <b>2021</b> , 5, 120-123	2
246	LEBER CONGENITAL AMAUROSIS DUE TO CEP290 MUTATIONS-SEVERE VISION IMPAIRMENT WITH A HIGH UNMET MEDICAL NEED: A Review. <b>2021</b> , 41, 898-907	10
245	Smart nano-micro platforms for ophthalmological applications: The state-of-the-art and future perspectives. <b>2021</b> , 270, 120682	7
244	Enhanced Transport and Permeation of a Polymeric Nanocarrier across the Retina by Mixing with ATP upon Intravitreal Injection. <b>2021</b> , 13,	0
243	Laser irradiation of ocular tissues to enhance drug delivery. <b>2021</b> , 596, 120282	3
242	Biologic Therapy and Treatment Options in Diabetic Retinopathy with Diabetic Macular Edema. <b>2021</b> , 16, 17-31	
241	Evaluation of Aqueous Flare Intensity in Eyes Undergoing Intravitreal Bevacizumab Therapy to Treat Neovascular Age-Related Macular Degeneration. <b>2021</b> , 12, 656774	3
240	Real-World Safety Outcomes of Intravitreal Ranibizumab Biosimilar (Razumab) Therapy for Choroidretinal Diseases. <b>2021</b> , 10, 337-348	4
239	Angle-closure Attack after Retinal Pigment Epithelium Double-tear and Hemorrhagic Retinal Detachment in Exudative Macular Degeneration. <b>2021</b> , 62, 577-582	
238	Questionnaire to Assess Life Impact of Treatment by Intravitreal Injections (QUALITII): Development of a patient-reported measure to assess treatment burden of repeat intravitreal injections. <b>2021</b> , 6, e000669	2

237	Expression of the Endoplasmic Reticulum Stress Marker GRP78 in the Normal Retina and Retinal Degeneration Induced by Blue LED Stimuli in Mice. <b>2021</b> , 10,	0
236	Therapeutic Efficacy of a Novel Acetylated Tetrapeptide in Animal Models of Age-Related Macular Degeneration. <b>2021</b> , 22,	0
235	Prolyl 3-Hydroxylase 2 Is a Molecular Player of Angiogenesis. <b>2021</b> , 22,	
234	Topical ketorolac as an adjunctive treatment with intravitreal bevacizumab in the management of diabetic macular edema: A double-masked placebo-controlled randomized clinical trial. <b>2021</b> , 259, 2949-2959	1
233	A New Bevacizumab Carrier for Intravitreal Administration: Focus on Stability. <b>2021</b> , 13,	3
232	Acute Bacterial Tenonitis and Conjunctivitis following Intravitreal Injection. <b>2021</b> , 12, 311-314	2
231	The Ophthalmology Surgical Competency Assessment Rubric for Intravitreal Injections (ICO-OSCAR:IVI). <b>2021</b> , 10,	0
230	Novel Peptide NT/K-CFY Derived from Kringle Structure of Neurotrypsin Inhibits Neovascularization. <b>2021</b> , 46, 1551-1558	
229	Next-generation contact lenses: Towards bioresponsive drug delivery and smart technologies in ocular therapeutics. <b>2021</b> , 161, 80-99	13
228	The P300/XBP1s/Herpud1 axis promotes macrophage M2 polarization and the development of choroidal neovascularization. <b>2021</b> , 25, 6709-6720	1
227	Effect of Aflibercept on Diabetic Retinopathy Severity and Visual Function in the RECOVERY Study for Proliferative Diabetic Retinopathy. <b>2021</b> , 5, 409-419	3
226	Emerging therapies and their delivery for treating age-related macular degeneration. <b>2021</b> ,	6
225	Management of Patients With DME With Good Visual Acuity in Routine Clinical Practice. <b>2021</b> , 52, 247-256	
224	Emerging biological therapies for the treatment of age-related macular degeneration. <b>2021</b> , 26, 193-207	3
223	Sphingosine 1-phosphate, a potential target in neovascular retinal disease. <b>2021</b> ,	0
222	Intraocular Pressure Elevation Following Intravitreal Anti-VEGF Injections: Short- and Long-term Considerations. <b>2021</b> , 30, 1019-1026	1
221	A Real-World Single-Centre Study of Patients with Diabetic Macular Oedema Who Wore a Home-Use Sleep Mask (Noctura 400) for One Year. <b>2021</b> , 2021, 6612126	1
220	Comparison of Two Different Intravitreal Injection Techniques. <b>2021</b> , 15, 2383-2389	0

219	Future Perspectives of Therapeutic, Diagnostic and Prognostic Aptamers in Eye Pathological Angiogenesis. <b>2021</b> , 10,	0
218	The HDAC/HSP90 Inhibitor G570 Attenuated Blue Light-Induced Cell Migration in RPE Cells and Neovascularization in Mice through Decreased VEGF Production. <b>2021</b> , 26,	0
217	Hypertensive cerebral hemorrhage with undetectable plasma vascular endothelial growth factor levels in a patient receiving intravitreal injection of aflibercept for bilateral diabetic macular edema: a case report. <b>2021</b> , 15, 403	4
216	Intravitreal injection associated rhegmatogenous retinal detachment: outcomes of a European analysis. <b>2021</b> , 259, 3655-3664	
215	Description and management of retinopathy of prematurity reactivation after intravitreal anti-vascular endothelial growth factor therapy. <b>2021</b> , 32, 468-474	0
214	The Challenges of Treating Neovascular Age-Related Macular Degeneration. <b>2021</b> ,	1
213	Systemic exposure following intravitreal administration of therapeutic agents: an integrated pharmacokinetic approach. 1. THR-149. <b>2021</b> , 48, 825-836	1
212	Largazole Inhibits Ocular Angiogenesis by Modulating the Expression of VEGFR2 and p21. <b>2021</b> , 19,	0
211	Safety of Receiving Anti-Vascular Endothelial Growth Factor Intravitreal Injection in Office-Based vs Operating Room Settings: A Meta-analysis. <b>2021</b> , 139, 1080-1088	1
210	Intravitreal Pharmacotherapies for Diabetic Macular Edema: A Report by the American Academy of Ophthalmology. <b>2021</b> ,	3
209	Effects of intravitreal injection of siRNA against caspase-2 on retinal and optic nerve degeneration in air blast induced ocular trauma. <b>2021</b> , 11, 16839	1
208	Isolated juxtapapillary retinal capillary haemangioblastoma and exudative maculopathy in an elderly patient without von Hippel-Lindau syndrome: combined proton beam radiotherapy and intravitreal anti-VEGF. <b>2021</b> , 14,	
207	Targeting vascular endothelial growth factor using retinal gene therapy. <b>2021</b> , 9, 1277	2
206	How Poloxamer Addition in Hyaluronic-Acid-Decorated Biodegradable Microparticles Affects Polymer Degradation and Protein Release Kinetics. <b>2021</b> , 11, 7567	
205	Pharmaceutical-loaded contact lenses as an ocular drug delivery system: A review of critical lens characterization methodologies with reference to ISO standards. <b>2021</b> , 44, 101487	10
204	Port delivery system: a novel drug delivery platform to treat retinal diseases. <b>2021</b> , 18, 1571-1576	4
203	Novel Peptide NT/K-CRS Derived from Kringle Structure of Neurotrypsin Inhibits Neovascularization and. <b>2021</b> , 37, 412-420	1
202	Acute and subacute macular and peripapillary angiographic changes in choroidal and retinal blood flow post-intravitreal injections. <b>2021</b> , 11, 19381	6

201	Polypoidal choroidal vasculopathy in a case of retinitis pigmentosa, successfully treated with intravitreal aflibercept. <b>2021</b> , 23, 101123	
200	Rapid formation of macular pucker following intravitreal ranibizumab injection for branch retinal vein occlusion. <b>2021</b> , 23, 101192	
199	Complement Factor B Mediates Ocular Angiogenesis through Regulating the VEGF Signaling Pathway. <b>2021</b> , 22,	1
198	Targeting nanocomposites with anti-oxidative/inflammatory/angiogenic activities for synergistically alleviating macular degeneration. <b>2021</b> , 24, 101156	1
197	Posterior cyclodialysis cleft following intravitreal injection. <b>2021</b> , 23, 101134	
196	Non-immediate drug hypersensitivity reactions secondary to intravitreal anti-vascular endothelial growth factors. <b>2021</b> , 1	1
195	Topical Triamcinolone Acetonide-Loaded Liposome Formulation Used as an Adjuvant to Intravitreal Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration. <b>2021</b> , 13,	1
194	Ocular Therapeutics and Molecular Delivery Strategies for Neovascular Age-Related Macular Degeneration (nAMD). <b>2021</b> , 22,	1
193	Hyaluronic Acid-Based Gold Nanoparticles for the Topical Delivery of Therapeutics to the Retina and the Retinal Pigment Epithelium. <b>2021</b> , 13,	2
192	Recombinant sulfated CCR2 peptide trap reduces retinal degeneration in mice. <b>2021</b> , 572, 171-177	0
191	Photo-Responsive Hydrogel Mns with Interlocking Control for Easy Extraction in Sustained Ocular Drug Delivery. <b>2021</b> ,	0
190	Effect of anti-vascular endothelial growth factor on the surgical outcome of neovascular glaucoma: An overview and meta-analysis. <b>2021</b> , 100, e27326	2
189	Non-neglectable therapeutic options for age-related macular degeneration: A promising perspective from traditional Chinese medicine. <b>2022</b> , 282, 114531	2
188	siRNA Therapeutics in Ocular Diseases. <b>2021</b> , 2282, 417-442	1
187	Standard Operating Procedures for Common Laboratory Animal Ocular Procedures. <b>2018</b> , 27-44	1
186	Preclinical challenges for developing long acting intravitreal medicines. <b>2020</b> , 153, 130-149	9
185	New therapeutic targets in the treatment of age-related macular degeneration. <b>2020</b> , 95, 75-83	7
184	Use of biomaterials for sustained delivery of anti-VEGF to treat retinal diseases. <i>Eye</i> , <b>2020</b> , 34, 1341-1354.	27

183	Update on Anti-Vascular Endothelial Growth Factor Safety for Retinopathy of Prematurity. <b>2020</b> , 9, 358-368	7
182	Anti-VEGF therapy: higher potency and long-lasting antagonism are not necessarily better. <b>2019</b> , 129, 3032-3034	17
181	Retinal Inhibition of CCR3 Induces Retinal Cell Death in a Murine Model of Choroidal Neovascularization. <b>2016</b> , 11, e0157748	9
180	Treatment of Coats Disease: an analysis of pooled results. <b>2019</b> , 12, 668-674	5
179	BMP9/ALK1 inhibits neovascularization in mouse models of age-related macular degeneration. <b>2016</b> , 7, 55957-55969	20
178	Advanced Hydrogels Based Drug Delivery Systems for Ophthalmic Delivery. <b>2019</b> , 13, 291-300	6
177	Nanotherapies for the Treatment of Age-Related Macular Degeneration (AMD) Disease: Recent Advancements and Challenges. <b>2019</b> , 13, 283-290	3
176	Comparative Safety of Bevacizumab, Ranibizumab, and Aflibercept for Treatment of Neovascular Age-Related Macular Degeneration (AMD): A Systematic Review and Network Meta-Analysis of Direct Comparative Studies. <b>2020</b> , 9,	23
175	Phosphorylation of STAT3 and ERBB2 mediates hypoxia-induced VEGF release in ARPE-19 cells. <b>2020</b> , 22, 2733-2740	1
174	All India Ophthalmological Society members Survey: Practice pattern of intravitreal anti-vascular endothelial growth factor injection. <b>2020</b> , 68, 1095-1098	7
173	Pars-plana fluid aspiration for positive vitreous cavity pressure in anterior segment surgeries. <b>2018</b> , 66, 565-567	5
172	Intravitreal Injections of Bevacizumab Plus Methotrexate versus Bevacizumab Alone for the Treatment of Diabetic Macular Edema: A Randomized, Sham-Controlled Trial. <b>2020</b> , 32, 164-169	4
171	Vascular permeability in retinopathy is regulated by VEGFR2 Y949 signaling to VE-cadherin. <b>2020</b> , 9,	22
170	Chitosan-Coated PLGA Nanoparticles Encapsulating Triamcinolone Acetonide as a Potential Candidate for Sustained Ocular Drug Delivery. <b>2021</b> , 13,	14
169	Risk of Posterior Capsular Rupture during Phacoemulsification in Patients with the History of Anti-VEGF Intravitreal Injections: Results from the Pan-American Collaborative Retina Study (PACORES) Group. <b>2021</b> , 2021, 5591865	
168	Targeting senescent retinal pigment epithelial cells facilitates retinal regeneration in mouse models of age-related macular degeneration. <b>2021</b> , 43, 2809-2833	5
167	Suprachoroidal delivery of bevacizumab in rabbit in vivo eyes: Rapid distribution throughout the posterior segment. <b>2021</b> , 169, 200-210	2
166	Conbercept for Treatment of Neovascular Age-Related Macular Degeneration and Visual Impairment due to Diabetic Macular Edema or Pathologic Myopia Choroidal Neovascularization: A Systematic Review and Meta-Analysis. <b>2021</b> , 12, 696201	2

- 165 Antiproliferative and Mitochondrial Protective Effects of Apigenin in an Oxygen-Induced Retinopathy Mouse Model. **2021**, 37, 580-590 0
- 164 Long Term Intraocular Pressure Changes after Intravitreal Injections. **2017**, 17, 14-16
- 163 Penetration Routes to Retina and Posterior Segment. **2018**, 69-81
- 162 [Impact of antiangiogenic therapy on ocular blood flow and microcirculation in diabetic macular edema]. **2018**, 134, 3-10 3
- 161 Encyclopedia of Ophthalmology. **2018**, 151-158
- 160 Nanomedicine-Based Delivery to the Posterior Segment of the Eye: Brighter Tomorrow. **2018**, 195-212 1
- 159 Colloidal Carrier Systems for Transscleral Drug Delivery. **2018**, 229-239
- 158 Ref-1/APE1 inhibition with novel small molecules blocks ocular neovascularization.
- 157 Cataract with posterior capsule rupture following intravitreal injection. **2019**, 67, 1729
- 156 Lipidomics reveal the protective effects of a vegetable-derived isothiocyanate against retinal degeneration. **2019**, 8, 1067
- 155 Posterior vitreous detachment rate following intravitreal dexamethasone injection. **2019**, 12, 1298-1303 1
- 154 Lipidomics reveal the protective effects of a vegetable-derived isothiocyanate against retinal degeneration. 8, 1067 1
- 153 Hemodynamic Change after Intravitreal Anti-vascular Endothelial Growth Factor Injection. **2020**, 5, 23-28
- 152 Subliminal Laser as Additional Therapy to Reduce Intravitreal Injection Number for the Patients with Macular Diseases. **2020**, 18, 45-47
- 151 Posterior tractional membranes following anti-vascular endothelial growth factor for retinopathy of prematurity. **2020**, 0
- 150 Lipidomics reveal the protective effects of a vegetable-derived isothiocyanate against retinal degeneration. 8, 1067
- 149 Task shifting of intravitreal injections from physicians to nurses: a qualitative study. **2021**, 21, 1185 0
- 148 Medication Trends for Age-Related Macular Degeneration. **2021**, 22, 5

- 147 Retinopathy of Prematurity. **2020**, 1-28
- 146 The Role of Pars Plana Vitrectomy (PPV) for the Treatment of Diabetic Macular Edema (DME). **2020**, 365-374
- 145 Lipidomics reveal the protective effects of a vegetable-derived isothiocyanate against retinal degeneration. **8**, 1067
- 144 Analysis of topical dosing and administration effects on ocular drug delivery in a human eyeball model using computational fluid dynamics. **2021**, 141, 105016 1
- 143 Intravitreal vascular endothelial growth factors hypertension, proteinuria, and renal injury: a concise review. **2022**, 31, 47-56 0
- 142 Assessment and management of retinopathy of prematurity in the era of anti-vascular endothelial growth factor (VEGF). **2021**, 101018 3
- 141 Shikonin alleviates choroidal neovascularization by inhibiting proangiogenic factor production from infiltrating macrophages. **2021**, 213, 108823 1
- 140 Systemic Drug Delivery to the Posterior Segment of the Eye: Overcoming Blood Retinal Barrier Through Smart Drug Design and Nanotechnology. **2021**, 219-269
- 139 Lipidomics reveal the protective effects of a vegetable-derived isothiocyanate against retinal degeneration. **8**, 1067
- 138 The Effect of a 0.1% Bromfenac Solution on Diabetic Macular Edema. **2020**, 61, 1273-1278
- 137 Use of Anti-VEGF Drugs in Retinal Vein Occlusions. **2020**, 21, 1181-1193 2
- 136 Comment on: Aflibercept for recurrent or recalcitrant polypoidal choroidal vasculopathy in Indian eyes: Early experience. **2018**, 66, 348-349 2
- 135 Impact of systemic parameters before commencing anti-vascular endothelial growth factor therapy for diabetic macular edema - Pan-Indian survey of retina specialists. **2021**, 69, 3273-3278
- 134 Microneedle scleral patch for minimally invasive delivery of triamcinolone to the posterior segment of eye. **2021**, 121305 2
- 133 Efficacy of Large Optic Intraocular Lenses in Myopic Eyes with Posterior Segment Pathology. **2021**, 1
- 132 Real-world incidence of endophthalmitis after intravitreal anti-VEGF injection: Common Data Model in ophthalmology. **2021**, e2021097 1
- 131 Short-term Safety Evaluation of Resident-performed Intravitreal Injection. **2021**, 62, 1509-1517
- 130 Combination intravitreal anti-vascular endothelial growth factor inhibitors and macular laser photocoagulation relative to intravitreal injection monotherapy in macular oedema secondary to retinal vein occlusion: a meta-analysis of randomized controlled trials. *Eye*, **2021**, 4-4



129	Feasibility of Therapeutic Ultrasound Application in Topical Scleral Delivery of Avastin. <b>2021</b> , 10, 2	1
128	Delivery of nVEGF <sub>i</sub> using AAV8 for the treatment of neovascular age-related macular degeneration.. <b>2022</b> , 24, 210-221	0
127	Vitamin E and preterm infants. <b>2021</b> , 180, 13-13	1
126	Non-arteritic anterior ischemic optic neuropathy after intravitreal aflibercept for age-related macular degeneration. <b>2020</b> ,	0
125	A Novel Approach for Development of Intraocular Biodegradable Ranibizumab Implant: A Solution for Stability of Protein Activity. <b>2021</b> , 11, 632-642	0
124	Visual outcomes in diabetic macular edema patients after avastin injection. <b>2020</b> , 9, 189-192	
123	Topical noninvasive retinal drug delivery of a tyrosine kinase inhibitor: 3% cediranib maleate cyclodextrin nanoparticle eye drops in the rabbit eye.. <b>2022</b> ,	0
122	Characterization and validation of a chronic retinal neovascularization rabbit model by evaluating the efficacy of anti-angiogenic and anti-inflammatory drugs.. <b>2022</b> , 15, 15-22	0
121	Transient Vision Loss Associated with Pre-Filled Aflibercept Syringes: A Case Series and Analysis of Injection Force. <b>2022</b> , 100115	0
120	Current Management of Diabetic Macular Edema.	1
119	Real-world effectiveness of screening programs for age-related macular degeneration: amended Japanese specific health checkups and augmented screening programs with OCT or AI.. <b>2022</b> , 66, 19-32	0
118	Ophthalmic dosage forms for drug delivery to posterior segment. 1	1
117	Importance of careful clinical examination and multimodal imaging before injecting intravitreal steroid. <b>2022</b> , 10, 35	
116	Bone marrow-derived mononuclear stem cells in the treatment of retinal degenerations.. <b>2022</b> , 17, 1937-1944	0
115	Safety Measures for Maintaining Low Endophthalmitis Rate after Intravitreal Anti-Vascular Endothelial Growth Factor Injection before and during the COVID-19 Pandemic.. <b>2022</b> , 11,	0
114	Nanotechnology-Abetted Astaxanthin Formulations in Multimodel Therapeutic and Biomedical Applications.. <b>2021</b> ,	6
113	Impact of Injection Protocol Selection by Retina Specialists on Clinical Outcomes in Patients with Diabetic Macular Edema.. <b>2021</b> , 12,	0
112	Ocular Suspension and Nanosuspension Products: Formulation Development Considerations. <b>2021</b> , 317-347	

111	Ophthalmic Product Development for Biologics. <b>2021</b> , 463-509	
110	Biodistribution of Cy5-labeled Thiolated and Methylated Chitosan-Carboxymethyl Dextran Nanoparticles in an Animal Model of Retinoblastoma.. <b>2022</b> , 17, 58-68	1
109	Alteration of plasma von Willebrand factor in the treatment of retinal vein occlusion with cystoid macular edema.	
108	Current Development, Obstacle and Futural Direction of Induced Pluripotent Stem Cell and Mesenchymal Stem Cell Treatment in Degenerative Retinal Disease.. <b>2022</b> , 23,	1
107	Treatment and prophylaxis of radiation optic neuropathy: A systematic review and meta-analysis.. <b>2022</b> , 11206721221085409	0
106	Simultaneous Release of Aflibercept and Dexamethasone from an Ocular Drug Delivery System.. <b>2022</b> , 1-9	2
105	Effect Modification by Indication to the Risks of Major Thromboembolic Adverse Events in Patients Receiving Intravitreal Anti-Vascular Endothelial Growth Factor Treatment: A Population-Based Retrospective Cohort Study.. <b>2022</b> , 36, 205	1
104	Self-plugging microneedle (SPM) for intravitreal drug delivery.. <b>2022</b> , e2102599	4
103	The Age-Related Macular Degeneration (AMD)-Preventing Mechanism of Natural Products. <b>2022</b> , 10, 678	
102	Management of acute proliferative diabetic retinopathy related complications during the first COVID-19 wave.. <b>2022</b> , 22, 119	
101	Serine/arginine rich protein kinase-1 (SRPK1) inhibition for the treatment of diabetic retinopathy.. <b>2022</b> ,	0
100	Galectin-1 and -3 in high amounts inhibit angiogenic properties of human retinal microvascular endothelial cells in vitro.. <b>2022</b> , 17, e0265805	0
99	Real-World Data on Intravitreal Aflibercept for Macular Edema Secondary to Central Retinal Vein Occlusion: 24-Month Outcomes.. <b>2022</b> , 16, 579-592	1
98	The changing landscape for the management of patients with neovascular AMD: brolocizumab in clinical practice.. <i>Eye</i> , <b>2022</b> ,	4.4 1
97	A hypoxia-regulated retinal pigment epithelium-specific gene therapy vector reduces choroidal neovascularization in a mouse model.. <b>2022</b> ,	0
96	Update on Retinal Drug Toxicities.. <b>2021</b> , 9, 1-10	1
95	Super-Resolution Imaging and Optomechanical Manipulation Using Optical Nanojet for Nondestructive Single-Cell Research. <b>2022</b> , 3, 2100233	1
94	Specific ablation of PDGFR $\beta$ -overexpressing pericytes with antibody-drug conjugate potently inhibits pathologic ocular neovascularization in mouse models. <b>2021</b> , 1,	

- 93 Ten-year mortality and long-term visual acuity outcomes in patients with exudative age-related macular degeneration treated with intravitreal anti-vascular endothelial growth factor injections.. **2021,**
- 92 Therapy of Pseudoxanthoma Elasticum: Current Knowledge and Future Perspectives.. **2021, 9,** 0
- 91 [Artificial intelligence in the management of anti-VEGF treatment: the Vienna fluid monitor in clinical practice].. **2022, 119, 520** 0
- 90 Recent progress in the use of thermogelling polymers for treatment of ophthalmic conditions.
- 89 Preliminary Research of Main Components of Dll4/ Notch-VEGF Signaling Pathway Under High-Glucose Stimulation in vitro.. **2022, 15, 1165-1171**
- 88 Comment on: Aflibercept for recurrent or recalcitrant polypoidal choroidal vasculopathy in Indian eyes: Early experience. **2018, 66, 348** 2
- 87 Ocular adverse effects of therapeutic biologics.. **2022, 14, 25158414211070878**
- 86 Retinopathy of Prematurity. **2022, 6737-6764**
- 85 The use of autologous mesenchymal stem cells in complications of diabetes mellitus, in particular diabetic retinopathy: inputs and insights. **2022, 19, 9-13**
- 84 Fluorescent Nanosystems for Drug Tracking and Theranostics: Recent Applications in the Ocular Field. **2022, 14, 955** 0
- 83 Harnessing retinal phagocytes to combat pathological neovascularization in ischemic retinopathies?. **2022, 474, 575-590** 0
- 82 Estimating ranibizumab injection numbers and visual acuity at 12 months based on 2-month data on branch retinal vein occlusion treatment.. **2022, 12, 7661**
- 81 Controlled release of naringenin from soft hydrogel contact lens: An investigation into lens critical properties and in vitro release.. **2022, 121793** 2
- 80 Polymer based sustained drug delivery to the ocular posterior segment: barriers and future opportunities for the treatment of neovascular pathologies.. **2022, 114342** 5
- 79 Incidence, Risk Factors and Outcomes of Rhegmatogenous Retinal Detachment after Intravitreal Injections of Anti-Vascular Endothelial Growth Factor for Retinal Diseases: Data from the Fight Retinal Blindness! Registry.. **2022,**
- 78 Combination of pigment epithelium derived factor with anti-vascular endothelial growth factor therapy protects the neuroretina from ischemic damage. **2022, 151, 113113**
- 77 Bioactive extracellular vesicles from a subset of endothelial progenitor cells rescue retinal ischemia and neurodegeneration. 0
- 76 Deletion of Tgf $\beta$  signal in activated microglia prolongs hypoxia-induced retinal neovascularization enhancing Igf1 expression and retinal leukostasis. 1

75	Targeted drug delivery to the retinal pigment epithelium: Untapped therapeutic potential for retinal diseases. <b>2022,</b>	1
74	Intravitreal aflibercept for diabetic macular edema in real-world clinical practice in Japan: 24-month outcomes.	2
73	Phenylboronic acid modified hydrogel materials and their potential for use in contact lens based drug delivery. 1-15	
72	Effect of nano-encapsulation using human serum albumin on anti-angiogenesis activity of bevacizumab to target corneal neovascularization: Development, optimization and in vitro assessment. <b>2022,</b>	
71	Evaluation of YouTube videos as a patient information source on intravitreal injection procedures. <b>2022,</b>	
70	CMV retinitis and subsequent acute cystoid macular oedema after treatment with vitreous ganciclovir injection: a case report. <b>2022, 22,</b>	0
69	Personalized treatment supported by automated quantitative fluid analysis in active neovascular age-related macular degeneration (nAMD) phase III, prospective, multicentre, randomized study: design and methods. <i>Eye,</i>	4-4
68	Suppression of myeloid Pfkfb3-driven glycolysis protects mice from choroidal neovascularization.	0
67	Hyaluronic Acid: Its Versatile Use in Ocular Drug Delivery with a Specific Focus on Hyaluronic Acid-Based Polyelectrolyte Complexes. <b>2022, 14, 1479</b>	1
66	Submacular Hemorrhage Following Aflibercept Intravitreal Injection: A Report of Two Cases. <b>2022,</b>	
65	Advances in cell therapies using stem cells/progenitors as a novel approach for neurovascular repair of the diabetic retina. <b>2022, 13,</b>	1
64	Long-acting ocular drug delivery technologies with clinical precedent. 1-17	0
63	Incidence and Visual Outcomes of Endophthalmitis After Intravitreal Injection of Dexamethasone Implant vs Ranibizumab. 247412642211093	
62	Zebrafish ( <i>Danio rerio</i> ) Is an Economical and Efficient Animal Model for Screening Potential Anti-cataract Compounds. <b>2022, 11, 21</b>	0
61	Targeting circRNA-MAP4K2 for the treatment of diabetes-induced retinal vascular dysfunction. <b>2022, 14, 6255-6268</b>	1
60	Risk, Prevalence, and Progression of Glaucoma in Eyes with Age-Related Macular Degeneration Treated with Intravitreal Anti-VEGF Injections. <b>2022,</b>	
59	Pathologically high intraocular pressure disturbs normal iron homeostasis and leads to retinal ganglion cell ferroptosis in glaucoma.	1
58	Dexamethasone Loaded Electrospun Nanocomposite Ocular Insert: In-vitro Drug Release and Mechanical Assessment. <b>2022, 12,</b>	

- 57 Therapeutic Ultrasound for Topical Corneal Delivery of Macromolecules. **2022**, 11, 23
- 56 Der Intraokulardruck nach Netzhauteingriffen.
- 55 Long-acting formulation strategies for protein and peptide delivery in the treatment of PSED. **2022**, 350, 538-568 1
- 54 Nanotechnology-based formulations to amplify intraocular bioavailability. **2022**, 14, 25158414221123 0
- 53 Pharmacotherapy of retinal diseases. **2022**, 325-331 0
- 52 Non-Invasive Iontophoretic Delivery of Cytochrome c to the Posterior Segment and Determination of Its Ocular Biodistribution. **2022**, 14, 1832 0
- 51 Targeting proliferative retinopathy: Arginase 1 limits vitreoretinal neovascularization and promotes angiogenic repair. **2022**, 13, 0
- 50 Brucizumab for the Treatment of Degenerative Macular Conditions: A Review of Clinical Studies. Volume 16, 2659-2680 1
- 49 Systemic Administration of Pegylated Arginase-1 Attenuates the Progression of Diabetic Retinopathy. **2022**, 11, 2890 0
- 48 Alteration of plasma von Willebrand factor in the treatment of retinal vein occlusion with cystoid macular edema. **2022**, 17, e0264809 0
- 47 Design, construction and in vivo functional assessment of a hinge truncated sFLT01. 0
- 46 A Paradigm Shift in the Management Approaches of Proliferative Diabetic Retinopathy: Role of Anti-VEGF Therapy. Volume 16, 3005-3017 0
- 45 A retrospective, single-center cohort study on complications after dental extractions in patients taking biologic agents. **2022**, 0
- 44 Sustained Release of Heme-Albumin as a Potential Novel Therapeutic Approach for Age-Related Macular Degeneration. 0
- 43 Membranoproliferative glomerulonephritis after intravitreal vascular growth factor inhibitor injections: a case report and review of the literature. 0
- 42 Three Monthly Injections Versus One Initial Injection of Ranibizumab for the Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion: 12-Month Results of a Prospective Randomized Study. **2022**, 11, 2309-2320 0
- 41 Anticancer potential of oroxylin A: from mechanistic insight to synergistic perspectives. 1
- 40 Microneedle-based ocular drug delivery systems ¶recent advances and challenges. 13, 1167-1184 0

- 39 Molecular mechanism of VEGF and its role in pathological angiogenesis. 0
- 38 Pulmonary function in school-age children following intravitreal injection of bevacizumab for retinopathy of prematurity. **2022**, 12, 0
- 37 The Role of Angiopoietins in Neovascular Diabetes-Related Retinal Diseases. **2022**, 13, 1811-1821 1
- 36 Oral administration of CU06-1004 attenuates vascular permeability and stabilizes neovascularization in retinal vascular diseases. **2023**, 939, 175427 0
- 35 Faricimab in the Treatment Landscape for Retinal Diseases: A Review. **2022**, 16, 92 0
- 34 Novel therapies for proliferative retinopathies. **2022**, 13, 204062232211403 0
- 33 Ophthalmic Solution of Smart Supramolecular Peptides to Capture Semaphorin 4D against Diabetic Retinopathy. 2203351 0
- 32 Retinopathy of prematurity: A review of pathophysiology and signaling pathways. **2022**, 1
- 31 A novel bispecific fusion protein targeting C3b/C4b and VEGF in Patients with nAMD: A Randomized, Open-label Phase 1b Study. **2022**, 1
- 30 In-situ nanomicelle forming microneedles of poly NIPAAm-b-poly glutamic acid for trans-scleral delivery of dexamethasone. **2022**, 1
- 29 Suppression of Pathological Ocular Neovascularization by a Small Molecular Multi-Targeting Kinase Inhibitor, DCZ19903. **2022**, 11, 8 0
- 28 Corneal biomechanical assessment via ocular response analyzer following intravitreal aflibercept therapy. 0
- 27 Laser microporation facilitates topical drug delivery: a comprehensive review about preclinical development and clinical application. 1-24 0
- 26 Quantifying burden of intravitreal injections: questionnaire assessment of life impact of treatment by intravitreal injections (QUALITII). **2022**, 7, e001188 0
- 25 A Nonrandomized Phase 2 Trial of EG-Mirotin, a Novel, First-in-Class, Subcutaneously Deliverable Peptide Drug for Nonproliferative Diabetic Retinopathy. **2023**, 59, 178 0
- 24 Repeated Topical Administration of 3 nm Cerium Oxide Nanoparticles Reverts Disease Atrophic Phenotype and Arrests Neovascular Degeneration in AMD Mouse Models. 0
- 23 Down-regulation of HuR inhibits pathological angiogenesis in oxygen-induced retinopathy. **2023**, 227, 109378 1
- 22 Role of flavonoids in age-related macular degeneration. **2023**, 159, 114259 1

- 21 Chinese Herbal Medicine Combined with Intravitreal Antivascular Growth Factor Agents in Treatment of Macular Edema Secondary to Retinal Vein Occlusion: A Systematic Review and Meta-Analysis. **2022**, 2022, 1-13 ○
- 20 Safety of intraocular anti-VEGF antibody treatment under in vitro HTLV-1 infection. 13, ○
- 19 MicroRNA-21: A critical underestimated molecule in diabetic retinopathy. **2023**, 859, 147212 ○
- 18 STRICT PRO RE NATA VERSUS TREAT-AND-EXTEND REGIMENS IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. **2023**, 43, 420-432 ○
- 17 Upadacitinib inhibits corneal inflammation and neovascularization by suppressing M1 macrophage infiltration in the corneal alkali burn model. **2023**, 116, 109680 ○
- 16 Optical coherence tomography and Scheimpflug imaging of the iridocorneal angle following intravitreal injection of different medications: A longitudinal analysis. **2023**, 41, 103319 ○
- 15 Effective treatment of retinal neovascular leakage with fusogenic porous silicon nanoparticles delivering VEGF-siRNA. **2022**, 17, 2089-2108 ○
- 14 Advances in Polysaccharide- and Synthetic Polymer-Based Vitreous Substitutes. **2023**, 15, 566 ○
- 13 Role of Anti-Vascular Endothelial Growth Factor (Anti-VEGF) in the Treatment of Retinopathy of Prematurity: A Narrative Review in the Context of Middle-Income Countries. Volume 14, 59-69 ○
- 12 Intraocular siRNA Delivery Mediated by Penetratin Derivative to Silence Orthotopic Retinoblastoma Gene. **2023**, 15, 745 ○
- 11 Improving retinal vascular endothelial cell tropism through rational rAAV capsid design. ○
- 10 Endostatin and Cancer Therapy: A Novel Potential Alternative to Anti-VEGF Monoclonal Antibodies. **2023**, 11, 718 ○
- 9 A comparative study between the possible protective role of melatonin versus its combination with adipose derived-mesenchymal stem cells on experimentally induced diabetic retinopathy in adult male albino rats (Histological and immunohistochemical study). 1-15 ○
- 8 MMP9-Responsive Graphene Oxide Quantum Dot-Based Nano-in-Micro Drug Delivery System for Combinatorial Therapy of Choroidal Neovascularization. 2207335 ○
- 7 Comparing interventions for chronic central serous chorioretinopathy: A network meta-analysis. **2023**, ○
- 6 Pulsed Ultrasound-Mediated Enhancement on Transscleral and Transconjunctival Fluorescein Sodium Delivery to Rabbit Eye In Vivo. **2023**, 39, 175-184 ○
- 5 Properties of Poly (Lactic-co-Glycolic Acid) and Progress of Poly (Lactic-co-Glycolic Acid)-Based Biodegradable Materials in Biomedical Research. **2023**, 16, 454 ○
- 4 Intravitreal Fluocinolone Acetonide Implant (ILUVIEN® ) for the Treatment of Retinal Conditions. A Review of Clinical Studies. Volume 17, 961-975 ○

- 3 Polymer coated polymeric microneedles for intravitreal delivery of dexamethasone. **2023**, 109467 ○
- 2 Nanoparticles as drug delivery agents for managing diabetic retinopathy. **2023**, 329-364 ○
- 1 Ocular therapies with biomacromolecules: From local injection to eyedrop and emerging noninvasive delivery strategies. **2023**, 197, 114864 ○